Bull
$1.95
Scenario price
$2.300
+1.135 (+49.35%)At close
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market.
Given the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

VisionSys AI Announces 1-for-10 ADS Reverse Split Plan

VisionSys AI Announces Reverse ADS Split Plan

VisionSys AI Inc. Secures $3 Million in Direct Offering

Petco Reports Strong Q4 Results, Shares Surge

VisionSys AI Inc (VSA) Executes 1-for-50 Reverse Stock Split, Reducing Shares to Approximately 554 Million
VisionSys AI Inc is a holding company primarily engaged in the development of brain-computer interface (BCI) technologies and related businesses. The Company's main business is developing, procuring, selling, and distributing BCI-enabled or BCI-adjacent products and solutions, and to provide related technical services. The BCI technologies are used in medical and healthcare-related applications, including functional rehabilitation, communication support, neurological disease-related monitoring and intervention, sensory assistance, and general wellness management. The Company mainly operates its businesses in the domestic market. It operates in the Healthcare sector.
Given the current price of $1.62, the stock has dropped 93.41% year-to-date and is trading near its 52-week low of $1.56. The RSI is at 28.371, indicating that the stock is oversold, but the forward P/E ratio of 23.4742 suggests high future earnings expectations that may not be met, especially with a significant projected net margin loss of -3853.03% in Q4 2025. The main risk is the company's extremely low current ratio of 0.05, indicating potential liquidity issues.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.